Graves Adrienne L.'s most recent trade in Harrow Health Inc was a trade of 5,248 RSU done . Disclosure was reported to the exchange on June 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Health Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2026 | 5,248 | 5,248 | - | - | RSU | |
| Ocular Therapeutix Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2026 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2026 | 14,000 | 64,000 (0%) | 0% | 0 | Common Stock | |
| Harrow Health Inc | Adrienne L. Graves | Director | Purchase of securities on an exchange or from another person at price $ 31.07 per share. | 18 May 2026 | 1,000 | 1,000 (0%) | 0% | 31.1 | 31,070 | Common Stock |
| Opus Genetics Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 24,367 | 127,514 | - | 0 | Common Stock | |
| Opus Genetics Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2026 | 23,643 | 103,147 | - | - | Common Stock | |
| Harrow Health Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 7,339 | 7,339 | - | - | RSU | |
| Ocular Therapeutix Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 14,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| Opus Genetics Inc | Graves L. Adrienne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 79,592 | 79,592 | - | - | Stock Option (Right to Buy) | |
| Opus Genetics Inc | Graves Adrienne L. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 79,504 | 79,504 | - | 0 | Common Stock | |
| Opus Genetics Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Oct 2024 | 172,874 | 172,874 | - | - | Stock Option (right to buy) | |
| Ocular Therapeutix Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2024 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2024 | 12,000 | 36,000 (0%) | 0% | 0 | Common Stock | |
| Harrow Health Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 8,347 | 8,347 | - | - | RSU | |
| Harrow Health Inc | Adrienne Graves L. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 3,119 | 3,119 | - | - | RSU | |
| Ocular Therapeutix Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 72,000 | 72,000 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Adrienne L. Graves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 24,000 | 24,000 (0%) | 0% | 0 | Common Stock |